


Substitute form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/525,797
(use as many sheets as necessary)		Filing Date	March 15, 2000
		First Named Inventor	Anagnostou et al.
		Group Art Unit	1642
		Examiner Name	Susan Ungar
Sheet	1 of 1	Attorney Docket Number	5218-39B

U.S. PATENT APPLICATIONS				
Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
	US-			

OTHER NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T
<i>Suz</i>	1.	Breymann et al. "Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers" <i>Br J Haematol.</i> 92(2):295-301 (1996)		
<i>Suz</i>	2.	Ito et al. "Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats" <i>Heart Vessel</i> 10(4):178-84 (1995)		
<i>Suz</i>	3.	Komatsu et al. "Multiple cerebral infarction after treatment with cisplatin" <i>Rinsho Shinkagaku</i> 36(3):499-502 (1996)		abstract

Examiner Signature  Date Considered 11/30/07

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.